Search

Your search keyword '"Marzolo, Marco"' showing total 10 results
Start Over Author "Marzolo, Marco"
10 results on '"Marzolo, Marco"'

1. Correction: Acute pulmonary embolism and cancer: findings from the COPE study

Author

Becattini, Cecilia, Cimini, Ludovica Anna, Bassanelli, Giorgio, Maggioni, Aldo P., Pomero, Fulvio, Lobascio, Ilaria, Enea, Iolanda, Pomata, Daniela P., Ruggieri, Maria Pia, Zalunardo, Beniamino, Novelli, Anna, Di Fusco, Stefania Angela, Triggiani, Marco, Marzolo, Marco, Fioravanti, Chiara, Agnelli, Giancarlo, Gonzini, Lucio, and Gulizia, Michele M.

Published
2024
Full Text
View/download PDF

2. Acute pulmonary embolism and cancer: findings from the COPE study

Author

Becattini, Cecilia, Cimini, Ludovica Anna, Bassanelli, Giorgio, Maggioni, Aldo P., Pomero, Fulvio, Lobascio, Ilaria, Enea, Iolanda, Pomata, Daniela P., Ruggieri, Maria Pia, Zalunardo, Beniamino, Novelli, Anna, Di Fusco, Stefania Angela, Triggiani, Marco, Marzolo, Marco, Fioravanti, Chiara, Agnelli, Giancarlo, Gonzini, Lucio, and Gulizia, Michele M.

Published
2024
Full Text
View/download PDF

3. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry

Author

Testa, Sophie, Cosmi, Benilde, Guazzaloca, Giuliana, Migliaccio, Ludovica, Poli, Daniela, Marcucci, Rossella, Maggini, Niccolò, Pengo, Vittorio, Falanga, Anna, Lerede, Teresa, Ruocco, Lucia, Martini, Giuliana, Pedrini, Simona, Bertola, Federica, Masciocco, Lucilla, Saracino, Pasquale, Benvenuto, Angelo, Vasselli, Claudio, Violi, Francesco, Pignatelli, Pasquale, Pastori, Daniele, Grandone, Elvira, Colaizzo, Donatella, Marzolo, Marco, Pinelli, Mauro, Mastroiacovo, Daniela, Ageno, Walter, Colombo, Giovanna, Bucherini, Eugenio, Serra, Domizio, Toma, Andrea, Barbera, Pietro, Paparo, Carmelo, Insana, Antonio, Rupoli, Serena, Malcangi, Giuseppe, Zighetti, Maddalena Loredana, Mangione, Catello, Lione, Domenico, Casasco, Paola, Nante, Giovanni, Tosetto, Alberto, Oriana, Vincenzo, Liberato, Nicola Lucio, Menichelli, Danilo, Antonucci, Emilia, and Palareti, Gualtiero

Published
2023
Full Text
View/download PDF

4. Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry

Author

Menichelli, Danilo, primary, Antonucci, Emilia, additional, Pignatelli, Pasquale, additional, Violi, Francesco, additional, Palareti, Gualtiero, additional, Pastori, Daniele, additional, Testa, Sophie, additional, Cosmi, Benilde, additional, Guazzaloca, Giuliana, additional, Migliaccio, Ludovica, additional, Poli, Daniela, additional, Marcucci, Rossella, additional, Maggini, Niccolò, additional, Pengo, Vittorio, additional, Falanga, Anna, additional, Lerede, Teresa, additional, Ruocco, Lucia, additional, Martini, Giuliana, additional, Pedrini, Simona, additional, Bertola, Federica, additional, Masciocco, Lucilla, additional, Saracino, Pasquale, additional, Benvenuto, Angelo, additional, Vasselli, Claudio, additional, Grandone, Elvira, additional, Colaizzo, Donatella, additional, Marzolo, Marco, additional, Pinelli, Mauro, additional, Mastroiacovo, Daniela, additional, Ageno, Walter, additional, Colombo, Giovanna, additional, Bucherini, Eugenio, additional, Serra, Domizio, additional, Toma, Andrea, additional, Barbera, Pietro, additional, Paparo, Carmelo, additional, Insana, Antonio, additional, Rupoli, Serena, additional, Malcangi, Giuseppe, additional, Zighetti, Maddalena Loredana, additional, Mangione, Catello, additional, Lione, Domenico, additional, Casasco, Paola, additional, Nante, Giovanni, additional, Tosetto, Alberto, additional, Oriana, Vincenzo, additional, and Liberato, Nicola Lucio, additional

Published
2023
Full Text
View/download PDF

5. Long-Term Outcomes in Two-Year Follow-Up after Primary Treatment in Patients with a Prior Venous Thromboembolic Event: A Prospective, Observational, Real-Life Study.

Author

Palareti, Gualtiero, Antonucci, Emilia, Bucherini, Eugenio, Caronna, Antonella, Chistolini, Antonio, Di Giorgio, Angela, Di Giulio, Rosella, Falanga, Anna, Fregoni, Vittorio, Garzia, Mariagrazia, Mastroiacovo, Daniela, Marzolo, Marco, Pancani, Roberta, Pastori, Daniele, Podda, Gian Marco, Rigoni, Anna Maria, Ria, Luigi, Sivera, Piera, Testa, Sophie, and Visonà, Adriana

Subjects
THROMBOEMBOLISM, DISEASE relapse, TREATMENT duration, ANTICOAGULANTS, PHYSICIANS
Abstract

Background: Patients with acute venous thromboembolism (VTE) need anticoagulation (AC) therapy for at least 3/6 months (primary treatment); after that period, they should receive a decision on the duration of therapy. Methods: This study examined the complications occurring during two years of follow-up (FU) in patients with a first VTE who were recruited in 20 clinical centers and had discontinued or prolonged AC. They were included in the START2-POST-VTE prospective observational study. Results: A total of 720 patients (53.5% males) who, after the completion of primary treatment, had received the decision to continue (n = 281, 39%; 76.1% with a DOAC) or discontinue (n = 439, 61%) AC were followed up for 2 years (total FU = 1318 years). The decision to prolong or suspend AC was made in similar proportions in patients with unprovoked or provoked index events. Courses of sulodexide treatment or Aspirin (100 mg daily) were prescribed to 20.3% and 4.5%, respectively, of the patients who discontinued AC. The bleeding rate was significantly higher in patients who extended AC (1.6% pt/y) than in those who stopped AC (0.1% pt/y; p = 0.001) and was higher in patients using standard-dose DOACs (3.1% pt/y) than in those using reduced-dose DOACs (0.4% pt/y). The recurrent VTE rates were similar between the two groups (2.2% pt/y during AC vs. 3% pt/y off AC). Conclusion: Physicians' decisions about AC duration were independent of the unprovoked/provoked nature of the index event. The bleeding rate was higher in patients who continued AC using standard-dose DOACs. Surprisingly, the rate of thrombotic recurrence was not different between those who continued or discontinued AC. Randomized studies comparing different procedures to decide on the duration of AC after a first VTE are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry

Author

Pastori, Daniele, primary, Antonucci, Emilia, additional, Violi, Francesco, additional, Palareti, Gualtiero, additional, Pignatelli, Pasquale, additional, Testa, Sophie, additional, Paoletti, Oriana, additional, Cosmi, Benilde, additional, Guazzaloca, Giuliana, additional, Migliaccio, Ludovica, additional, Poli, Daniela, additional, Marcucci, Rossella, additional, Maggini, Niccolò, additional, Pengo, Vittorio, additional, Falanga, Anna, additional, Lerede, Teresa, additional, Ruocco, Lucia, additional, Martini, Giuliana, additional, Pedrini, Simona, additional, Bertola, Federica, additional, Masciocco, Lucilla, additional, Saracino, Pasquale, additional, Benvenuto, Angelo, additional, Vasselli, Claudio, additional, Pastori, Daniele, additional, Grandone, Elvira, additional, Colaizzo, Donatella, additional, Marzolo, Marco, additional, Pinelli, Mauro, additional, Ageno, Walter, additional, Colombo, Giovanna, additional, Bucherini, Eugenio, additional, Serra, Domizio, additional, Toma, Andrea, additional, Barbera, Pietro, additional, Paparo, Carmelo, additional, Insana, Antonio, additional, Rupoli, Serena, additional, Malcangi, Giuseppe, additional, Zighetti, Maddalena Loredana, additional, Mangione, Catello, additional, Lione, Domenico, additional, Casasco, Paola, additional, Nante, Giovanni, additional, Tosetto, Alberto, additional, Oriana, Vincenzo, additional, and Liberato, Nicola Lucio, additional

Published
2019
Full Text
View/download PDF

8. Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism

Author

Pesavento, Raffaele, primary, Filippi, Lucia, additional, Palla, Antonio, additional, Visonà, Adriana, additional, Bova, Carlo, additional, Marzolo, Marco, additional, Porro, Fernando, additional, Villalta, Sabina, additional, Ciammaichella, Maurizio, additional, Bucherini, Eugenio, additional, Nante, Giovanni, additional, Battistelli, Sandra, additional, Muiesan, Maria Lorenza, additional, Beltramello, Giampietro, additional, Prisco, Domenico, additional, Casazza, Franco, additional, Ageno, Walter, additional, Palareti, Gualtiero, additional, Quintavalla, Roberto, additional, Monti, Simonetta, additional, Mumoli, Nicola, additional, Zanatta, Nello, additional, Cappelli, Roberto, additional, Cattaneo, Marco, additional, Moretti, Valentino, additional, Corà, Francesco, additional, Bazzan, Mario, additional, Ghirarduzzi, Angelo, additional, Frigo, Anna Chiara, additional, Miniati, Massimo, additional, and Prandoni, Paolo, additional

Published
2017
Full Text
View/download PDF

9. Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register.

Author

Antonucci, Emilia, Migliaccio, Ludovica, Abbattista, Maria, Caronna, Antonella, De Marchi, Sergio, Di Giorgio, Angela, Di Giulio, Rosella, Lerede, Teresa, Garzia, Maria Grazia, Martinelli, Ida, Mastroiacovo, Daniela, Marzolo, Marco, Montevecchi, Elisa, Pastori, Daniele, Pignatelli, Pasquale, Poli, Daniela, Ria, Luigi, Santoliquido, Angelo, Testa, Sophie, and Palareti, Gualtiero

Subjects
THROMBOEMBOLISM, VENOUS thrombosis, PATIENT preferences, MEDICAL registries, DECISION making
Abstract

Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d -dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

10. Antihypertensive Treatment in the Elderly and Very Elderly: Always 'the Lower, the Better?'

Author

Mazza, Alberto, Ramazzina, Emilio, Cuppini, Stefano, Armigliato, Michela, Schiavon, Laura, Rossetti, Ciro, Marzolo, Marco, Santoro, Giancarlo, Ravenni, Roberta, Zuin, Marco, Zorzan, Sara, Rubello, Domenico, and Casiglia, Edoardo

Subjects
Article Subject
Abstract

Arterial hypertension (HT) is age dependent and, with the prolongation of life expectancy, affects more and more elderly people. In the elderly, HT is a risk factor for organ damage and cardiovascular (CV) events. Both pharmacologic and nonpharmacologic reduction of blood pressure (BP) is associated with a corresponding decrease in systolic-diastolic or isolated systolic HT. Clinical trials have shown that BP lowering is associated with a decrease in stroke and other CV events. Therefore, BP reduction per se appears more important than a particular class of antihypertensive drugs. The benefit of antihypertensive treatment has been confirmed up to the age of 80 years, remaining unclear in the octogenarians. The benefit in lowering diastolic BP between 80 and 90 mmHg is well established, while that of lowering systolic BP below 140 mmHg requires further confirmations.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results